Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Chinese R/R Waldenstrom's Macroglobulinemia
NCT04042376Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ibrutinib in Waldenstrom macroglobulinemia (WM), sponsored by Janssen Pharmaceutical. Started Dec 2019; status: completed.
02
Drugs
ibrutinib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04042376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042376.